{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:10:44Z","timestamp":1790730644305,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.14283\/jpad.2022.34","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T02:44:58Z","timestamp":1648608298000},"page":"221-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["Aducanumab: Appropriate Use Recommendations Update"],"prefix":"10.1016","volume":"9","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Selkoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2022.34_bib1","unstructured":"U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs \u2014 Aducanumab. Reference ID 4807032. 2021["},{"key":"10.14283\/jpad.2022.34_bib2","series-title":"Guidance for Industry, Expedited Programs for Serious Conditions \u2014 Drugs and Biologics","author":"U.S. Food & Drug Administration","year":"2014"},{"issue":"4","key":"10.14283\/jpad.2022.34_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2022.34_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2022.34_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and beta-amyloid-targeting antibodies: a systematic review","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.14283\/jpad.2022.34_bib6","first-page":"e12101","article-title":"Symptomatic amyloid-related imaging abnormalities in an APOE epsilon4\/epsilon4 patient treated with aducanumab","volume":"12","author":"VandeVrede","year":"2020","journal-title":"Alzheimers Dement (Amst)."},{"key":"10.14283\/jpad.2022.34_bib7","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2022s disease treated with anti-amyloid beta therapy","author":"Barakos","year":"2022","journal-title":"J Prev Alz Dis"},{"issue":"3","key":"10.14283\/jpad.2022.34_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2022s disease: recommendations from the National Institute on Aging-Alzheimer\u2022s Association workgroups on diagnostic guidelines for Alzheimer\u2022s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.14283\/jpad.2022.34_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2022s disease: recommendations from the National Institute on Aging-Alzheimer\u2022s Association workgroups on diagnostic guidelines for Alzheimer\u2022s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"18","key":"10.14283\/jpad.2022.34_bib10","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1212\/WNL.0b013e3182a9f545","article-title":"Abeta-related angiitis: comparison with CAA without inflammation and primary CNS vasculitis","volume":"81","author":"Salvarani","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.14283\/jpad.2022.34_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease \u2014 one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.14283\/jpad.2022.34_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.14283\/jpad.2022.34_bib13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.14283\/jpad.2022.34_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.carj.2018.10.008","article-title":"Validation of an magnetic resonance imaging acquisition and review protocol for Alzheimer\u2022s disease and related disorders","volume":"70","author":"Asselin","year":"2022","journal-title":"Can Assoc Radiol J."},{"issue":"4","key":"10.14283\/jpad.2022.34_bib15","doi-asserted-by":"crossref","first-page":"e18865","DOI":"10.1097\/MD.0000000000018865","article-title":"The study on analysis of risk factors for severity of white matter lesions and its correlation with cerebral microbleeds in the elderly with lacunar infarction","volume":"99","author":"Zhou","year":"2020","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"10.14283\/jpad.2022.34_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","article-title":"Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial","volume":"30","author":"Sevigny","year":"2016","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"10.14283\/jpad.2022.34_bib17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.psym.2015.12.002","article-title":"Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia","volume":"57","author":"Degenhardt","year":"2016","journal-title":"Psychosomatics"},{"key":"10.14283\/jpad.2022.34_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum","author":"Jansen","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.14283\/jpad.2022.34_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2022s Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.14283\/jpad.2022.34_bib20","doi-asserted-by":"crossref","first-page":"e14408","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer\u2022s disease","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"14","key":"10.14283\/jpad.2022.34_bib21","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.34_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-neuro-071013-014300","article-title":"Apolipoprotein E in Alzheimer\u2022s disease: an update","volume":"37","author":"Yu","year":"2014","journal-title":"Annu Rev Neurosci"},{"issue":"3","key":"10.14283\/jpad.2022.34_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer\u2022s disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"issue":"9","key":"10.14283\/jpad.2022.34_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"10.14283\/jpad.2022.34_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1474-4422(18)30251-5","article-title":"Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study","volume":"17","author":"Yang","year":"2018","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.14283\/jpad.2022.34_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/NEN.0b013e31829a25b9","article-title":"APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in cerebral vasculature","volume":"72","author":"Nelson","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.14283\/jpad.2022.34_bib27","unstructured":"Sandrock A. Aducanumab for the treatment of Alzheimer\u2022s disease. U.S. Food & Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee. November 6, 2020. 2020."},{"issue":"3","key":"10.14283\/jpad.2022.34_bib28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3233\/JAD-210675","article-title":"Disclosing genetic risk of Alzheimer\u2022s disease to cognitively unimpaired older adults: indings from the study of knowledge and reactions to APOE testing (SOKRATES II)","volume":"84","author":"Largent","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"10.14283\/jpad.2022.34_bib29","doi-asserted-by":"crossref","first-page":"e0258646","DOI":"10.1371\/journal.pone.0258646","article-title":"Return of individual research results from genomic research: A systematic review of stakeholder perspectives","volume":"16","author":"Vears","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.14283\/jpad.2022.34_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0809578","article-title":"Disclosure of APOE genotype for risk of Alzheimer\u2022s disease","volume":"361","author":"Green","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.14283\/jpad.2022.34_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2022s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.14283\/jpad.2022.34_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2022s disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.14283\/jpad.2022.34_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11065-020-09472-2","article-title":"Decision-making competence in patients with Alzheimer\u2022s disease: a review of the literature","volume":"31","author":"Gaubert","year":"2021","journal-title":"Neuropsychol Rev"},{"key":"10.14283\/jpad.2022.34_bib34","article-title":"Decisions with patients and families regarding aducanumab in Alzheimer disease, with recommendations for consent: AAN position statement","author":"Chiong","year":"2021","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.34_bib35","author":"Coerver"},{"issue":"10","key":"10.14283\/jpad.2022.34_bib36","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of aducanumab for Alzheimer disease-the FDA\u2022s perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.14283\/jpad.2022.34_bib37","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2022s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2022.34_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2022s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2022.34_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer\u2022s disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.14283\/jpad.2022.34_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2022s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2022.34_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01953.x","article-title":"Differences between clinical trials and postmarketing use","volume":"57","author":"Martin","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.14283\/jpad.2022.34_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1532-5415.1997.tb02960.x","article-title":"Eligibility of Alzheimer\u2022s disease clinic patients for clinical trials","volume":"45","author":"Schneider","year":"1997","journal-title":"J Am Geriatr Soc"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:11:52Z","timestamp":1737339112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724003340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2274580724003340"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.34","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aducanumab: Appropriate Use Recommendations Update","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.34","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}